The European Patent Office Revokes the Broad Institute‘s CRISPR Patents
The Broad Institute has been dealt a big blow in its battle for CRISPR/Cas9 intellectual property, with the European Patent Office revoking one of its patents.
CRISPR/Cas9 has been hailed as the ‘scientific discovery of the century’ due to its capacity to modify the genome for the treatment of genetic diseases. The Broad Institute, set up by MIT and Harvard in 2004 to use genomics to improve human health, successfully obtained a patent from the US Patent Office for its use in eukaryotes. However, the European Patent Office (EPO) has revoked the first of several patents obtained by the Broad Institute, citing a clear lack of novelty.